{
    "organizations": [],
    "uuid": "37e6eb00071489a0ea3729f71d4b5108de1d5cac",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-announces/brief-paratek-pharmaceuticals-announces-proposed-private-offering-of-125-mln-of-convertible-senior-subordinated-notes-due-2024-idUSASC09WC1",
    "ord_in_thread": 0,
    "title": "BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Paratek Pharmaceuticals Inc:\n* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024\n* PARATEK PHARMACEUTICALS-INTENDS TO USE PROCEEDS, TOGETHER WITH EXISTING CAPITAL RESOURCES, TO FUND ONGOING AND FUTURE CLINICAL STUDIES OF OMADACYCLINE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T04:12:00.000+03:00",
    "crawled": "2018-04-19T15:23:26.026+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "paratek",
        "pharmaceutical",
        "inc",
        "paratek",
        "pharmaceutical",
        "announces",
        "proposed",
        "private",
        "offering",
        "million",
        "convertible",
        "senior",
        "subordinated",
        "note",
        "due",
        "paratek",
        "use",
        "proceeds",
        "together",
        "existing",
        "capital",
        "resource",
        "fund",
        "ongoing",
        "future",
        "clinical",
        "study",
        "omadacycline",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}